Levofloxacin use at an academic teaching institution

被引：5

作者：

Belliveau, PP

Brennan, WP

Rothman, AL

机构：

[1] UMassMem Med Ctr, Dept Pharm, Worcester, MA 01655 USA

[2] Massachusetts Coll Pharm & Hlth Sci, Boston, MA USA

[3] Boston Univ, Dept Family Med, Sch Med, Boston, MA 02215 USA

来源：

AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY | 2000年 / 57卷 / 19期

关键词：

D O I：

10.1093/ajhp/57.19.1791

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：1791 / 1793

页数：3

共 14 条

[1]

Ambrose P G, 1997, Conn Med, V61, P269

[2]

ARTIN SJ, 1998, ANN PHARMACOTHER, V32, P320

[3] Comparative tolerability of the newer fluoroquinolone antibacterials [J].

Ball, P ;

Mandell, L ;

Niki, Y ;

Tillotson, G .

DRUG SAFETY, 1999, 21 (05) :407-421

[4]

Blondeau JM, 1999, CLIN THER, V21, P3

[5] PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE [J].

COCKCROFT, DW ;

GAULT, MH .

NEPHRON, 1976, 16 (01) :31-41

[6] Levofloxacin and trovafloxacin: The next generation of fluoroquinolones? [J].

Ernst, ME ;

Ernst, EJ ;

Klepser, ME .

AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1997, 54 (22) :2569-2584

[7] A prediction rule to identify low-risk patients with community-acquired pneumonia [J].

Fine, MJ ;

Auble, TE ;

Yealy, DM ;

Hanusa, BH ;

Weissfeld, LA ;

Singer, DE ;

Coley, CM ;

Marrie, TJ ;

Kapoor, WN .

NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (04) :243-250

[8] Fluoroquinolone toxicity profiles: A review focusing on newer agents [J].

Lipsky, BA ;

Baker, CA .

CLINICAL INFECTIOUS DISEASES, 1999, 28 (02) :352-364

[9]

*ORTH PHARM, 1996, LEV PACK INS

[10] RELATIONSHIP BETWEEN QUINOLONE USE AND EMERGENCE OF CIPROFLOXACIN-RESISTANT ESCHERICHIA-COLI IN BLOOD-STREAM INFECTIONS [J].

PENA, C ;

ALBAREDA, JM ;

PALLARES, R ;

PUJOL, M ;

TUBAU, F ;

ARIZA, J .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (02) :520-524

← 1 2 →